Align Technology, Inc. (ALGN)
POSITIVEFundamental
76
Preço
$158.46
Capitalização de Mercado
$11.34B
Parte 1 · Quanto vale a empresa
Visão Geral
Align Technology makes Invisalign, a series of clear, custom-molded plastic trays that gradually straighten teeth as an alternative to metal braces, sold to orthodontists and general dentists who fit and monitor patients through the treatment. It also sells iTero intraoral scanners, which capture a 3D digital model of a patient's mouth used both to plan Invisalign treatment and, more broadly, for other dental and orthodontic work, plus the CAD/CAM software that runs the whole design and manufacturing process.
Como gera receita
Align earns Clear Aligner revenue per treatment case: a doctor orders a set of custom aligners, Align manufactures and ships them, and revenue is recognized as trays are delivered over the course of treatment. Systems and Services revenue comes from selling or leasing iTero scanners plus recurring CAD/CAM software and service fees. Because key aligner patents began expiring in 2017, pricing power now rests more on brand recognition, the doctor-training network and scanner ecosystem than on legal exclusivity.
Receita por segmento
Custom clear aligner trays for straightening teeth, sold per treatment case to orthodontists and general dentists worldwide.
iTero intraoral scanners plus the CAD/CAM software and services used to plan and manufacture both Invisalign and other dental work.
Vantagem competitiva
Marca · EstreitaInvisalign is the name patients ask for by default, built over two decades of marketing and a large trained network of certified doctors. But the aligner patents that once blocked competitors began expiring in 2017, and cheaper rivals plus direct-to-consumer and in-office 3D-printed alternatives have since chipped away at both volume growth and pricing.
O que impulsiona a procura
Moderadamente cíclicoStraightening teeth is largely elective and often paid out of pocket or through limited dental insurance, so case volumes soften when consumers pull back discretionary spending. Growth also depends on expanding into new international markets and younger teen patients, both of which move independently of any single economic cycle but are still sensitive to household budgets.
Principais riscos
- Patent expiry and low-cost competition — Key clear-aligner patents have expired in the US and abroad, letting lower-priced rivals and direct-to-consumer aligner services compete for the same patients and pressure the prices Align can charge.
- Discretionary consumer spending — Orthodontic treatment is often optional and expensive, so case starts slow when consumers are cautious about spending, even if their teeth alignment need has not changed.
- International and China exposure — A meaningful part of growth depends on international markets, including China, where local competitors, economic slowdown or regulatory change can reduce case volume independent of trends in the US.
- Intellectual property litigation — Align is involved in ongoing patent and other IP disputes with competitors and doctors; adverse rulings could restrict product features or require payments that reduce profitability.
Concentração de clientes
Align sells to hundreds of thousands of orthodontic and dental practices worldwide rather than a few large accounts, so no single customer represents a material share of revenue.
Os argumentos a favor
Buyers argue that Invisalign's brand recognition and trained doctor network still give it the largest share of a clear aligner market that keeps growing as more patients choose aligners over metal braces, with international expansion offering years of additional case growth.
Os argumentos contra
Sellers fear that patent expiry has permanently opened the door to cheaper competitors, that elective treatment spending is exposed to consumer caution, and that growth increasingly depends on international markets where Align's brand advantage is weaker.
Written by the editors, published on 18 de agosto de 2026
Direct competitors
Who this company fights with for the same customers
Generated on 23 de agosto de 2026 with claude-opus-5 — shared with all users
Its Ormco unit sells the Spark clear aligner system to the same orthodontists Invisalign is sold to, competing case by case on aligner material, software and treatment planning.
Sells SureSmile clear aligners and Primescan intraoral scanners to the same dental practices, overlapping with both of Align's businesses at once.
Its ClearCorrect aligner brand competes for the same orthodontic and general-dentist customers worldwide, pushed through Straumann's large European implant and digital-dentistry sales network.
The largest clear aligner maker in China and now expanding into Europe, Latin America and Asia, taking aligner cases directly from Invisalign in the markets Align counts on for growth.
Its Dental Solutions arm sells Clarity aligners, brackets and bonding systems to orthodontists, competing for the same orthodontic case volume.
Its TRIOS intraoral scanners are the main alternative to Align's iTero scanners in dental practices, competing for the chairside digital-scanning workflow.
Balanço & Liquidez
Receita
$4.14B
Últimos 12 meses (até 30/06/2026)
Resultado Líquido
$414M
Últimos 12 meses (até 30/06/2026)
Fluxo de Caixa Livre
$491M
Capital Próprio Total
$4.05B
Passivo Total
$2.18B
Rácio de Liquidez
1.40
Cobertura de Juros
-
Dívida/EBITDA
0.15
Resultados Por Ação
Receita & Resultado Líquido
Fluxo de Caixa Livre
Decomposição dos Resultados
Demonstração histórica
Margens ao longo do tempo
A dívida ao longo do tempo
Quanto pesa a dívida
Grelha do crescimento
Crescimento — Receitas
Estimativa de Valor Justo
Valor Justo
$122.06
Preço Atual
$158.46
Margem de Segurança
-29.8%
Intervalo de Valor Justo
$79.34 - $164.78
Métodos de Estimativa
Métricas de Avaliação
Rácio P/E
27.81
ROE
10.1%
Rácio P/B
2.68
P/FCF
17.90
Margem Bruta
68.0%
ROIC
9.6%
Radar de Rentabilidade
Value Creation (Economic Moat)
ROIC
9.6%
WACC
13.5%
ROIC − WACC
-3.9 pp
ROIC is below the cost of capital — the company is destroying value for every dollar invested.
Critérios de Análise Fundamental
Aprovado (22)
- EPS shows upward trend
- EPS CAGR 9.65%
- Price CAGR 5.39%
- ROIC 9.6%
- Gross Margin 68.0%
- P/FCF 17.90
- P/B Ratio 2.68
- Debt/Equity ratio
- Operating Margin 13.2%
- Positive Free Cash Flow
- CapEx intensity
- Current Ratio
- Debt/EBITDA
- Return on Tangible Assets
- Low reliance on intangibles
- ROE 10.1%
- Revenue Growth 5Y 10.3%
- Analyst Consensus 71% Buy
- Earnings Surprise avg 6.3%
- Earnings Quality (OCF/NI) 1.83
- Share Dilution -3.1%
- Piotroski F-Score 7/9
Reprovado (3)
- Price below Graham Number
- DCF valuation (Overvalued)
- Net Margin Trend 10.0% vs 11.0%
Indisponível (3)
- Dividend Payout NaN%
- Interest Coverage
- PEG Ratio (need PE > 0 and growth > 0)
Piotroski F-Score
Saúde financeira sólida
Qualidade dos Resultados
Alta qualidade: resultados respaldados por caixa
Diluição de Ações
A recomprar ações. Favorável ao acionista
Governação
Equipa Executiva
| Nome | Cargo | Idade |
|---|---|---|
| Mr. Joseph M. Hogan | President, CEO & Director | 68 |
| Mr. John F. Morici | CFO & Executive VP of Global Finance | 58 |
| Mr. Zelko Relic | Executive VP & CTO | 60 |
| Ms. Shirley Stacy | Vice President of Corporate Communications & Investor Relations | - |
| Richardson Jaime Holte | Executive Vice President of Global Human Resources | - |
| Ms. Sreelakshmi Kolli | Executive VP and Chief Product & Digital Officer | 50 |
| Mr. Srini Kaza | Executive Vice President of Research & Development | - |
| Dr. Mitra Derakhshan | Executive VP, Chief Clinical Officer, Global Treatment Planning & Clinical Services | - |
| Mr. David Carr | Executive VP and MD of EMEA | - |
| Mr. Frank Quinn | Executive VP & MD of Americas Region | - |
Risco de Auditoria
1
Risco do Conselho
4
Risco de Remuneração
9
Risco dos Direitos dos Acionistas
7
Parte 2 · O preço e o momento de entrar
Esta parte não serve para saber se a empresa vale: serve para escolher quando comprá-la, depois que os fundamentos te convenceram. Dentro: análise técnica, potencial, quedas históricas, exposição gama.
Latest News
Recent headlines for ALGN, sourced from Markets Gazette.
- 4/7/2026POSITIVEAlignment Stock Surges After 2.48% Medicare Rate Hike
Alignment Healthcare Inc. experienced a significant surge in its stock price following the Centers for Medicare & Medicaid Services (CMS) announcement of a 2.48% rate increase for 2027 Medicare Advantage and Part D programs. This favorable adjustment is expected to bolster the company's revenue streams and profitability, as these programs represent a substantial portion of Alignment Healthcare's business. Investors are reacting positively to the improved financial outlook, anticipating enhanced earnings and a stronger market position for the healthcare provider.
- 3/19/2026POSITIVEAlign Technology Shares Jump Following Report Of Large Elliott Position
Align Technology shares surged following news that activist investor Elliott Investment Management has taken a significant stake in the company. Elliott's involvement typically signals a push for strategic changes, often aimed at unlocking shareholder value. The move comes as Align Technology, the maker of Invisalign, faces challenges in its post-pandemic growth trajectory. Investors are likely interpreting this as a potential catalyst for operational improvements and a re-evaluation of the company's strategic direction, which could lead to enhanced financial performance.
- 3/19/2026NEUTRALElliott Builds Stake in Invisalign-Maker Align Technology
Hedge fund Elliott Investment Management has acquired a substantial stake in Align Technology Inc., the company renowned for its Invisalign clear aligners. This move by a prominent activist investor suggests potential for strategic changes or operational improvements within Align Technology. While the specific intentions of Elliott are not yet disclosed, such stake-building often precedes engagement with management to unlock shareholder value. Investors will be watching closely for any strategic shifts or performance enhancements that Elliott may advocate for, which could impact the company's future trajectory and stock performance.
via Markets Gazette